title: Developmental approaches in immunological control of acute myelogenous leukaemia.
abstract: After many years of hope and disillusionment, the possibility of utilizing immune-mediated approaches to control neoplastic clones has become a reality in various haematological malignancies. This is largely a consequence of the continuous advances in knowledge and the progressive development of more refined technologies that have led to a better understanding of the biology of the malignant cells and of the host immune system, to a more precise definition of disease entities and to the design of innovative therapeutic programmes. In this chapter, we will review different immunological strategies that have reached clinical practice in patients with acute myelogenous leukaemia (AML), the focus of this volume, and discuss pre-clinical developments that may in the near future translate into the design of new immunotherapeutic protocols for the management of AML. Treatment of AML with antibody directed therapy will also be discussed.
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, University 'La Sapienza', Via Benevento 6, Rome, 00161, Italy.
authors.forename: G F
authors.initials: GF
authors.lastname: Torelli
authors.forename: E
authors.initials: E
authors.lastname: Orsini
authors.forename: A
authors.initials: A
authors.lastname: Guarini
authors.forename: J
authors.initials: J
authors.lastname: Kell
authors.forename: R
authors.initials: R
authors.lastname: Foà
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D016219:Immunotherapy, Adoptive / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines